Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Raluca Ionescu-Ittu"'
Autor:
Elizabeth Marrett, Winghan Jacqueline Kwong, Jipan Xie, Ameur M. Manceur, Selvam R. Sendhil, Eric Wu, Raluca Ionescu-Ittu, Janakiraman Subramanian
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 531-544 (2023)
Abstract Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR TKIs) are established first-line treatments among patients with metastatic non-small cell lung cancer harboring EGFR-sensitizing mutations. Upon EGFR TKI resistance
Externí odkaz:
https://doaj.org/article/9caad38b62b441cfafd81f36ac1d42c7
Publikováno v:
Oncology and Therapy, Vol 11, Iss 4, Pp 481-493 (2023)
Abstract Introduction Many patients with human epidermal growth factor receptor-2-positive metastatic breast cancer (HER2+ mBC) require subsequent lines of therapy (LOTs) after being treated with pertuzumab and trastuzumab-based regimens in the first
Externí odkaz:
https://doaj.org/article/5dc0f4815a144e63b48a0f605991e2dc
Autor:
Alexander Russell-Smith, Riley Taiji, Paule Tétreault-Langlois, Samy Gallienne, Raluca Ionescu-Ittu, Francis Vekeman, Anthony Moorman, Michael Doubek, Saara Tikka, Amin Turki
Publikováno v:
HemaSphere, Vol 7, p e32403e2 (2023)
Externí odkaz:
https://doaj.org/article/8229811d97d345cdbb022b2122fe963f
Autor:
Peter Hur, Kathleen G. Lomax, Raluca Ionescu-Ittu, Ameur M. Manceur, Jipan Xie, Jordan Cammarota, Raju Gautam, Navneet Sanghera, Nina Kim, Alexei A. Grom
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 19, Iss 1, Pp 1-13 (2021)
Abstract Background Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood. We aimed
Externí odkaz:
https://doaj.org/article/895a29c829b840f387ab20d693d70cfe
Autor:
Menno Vergeer, Wendela L. deRanitz‐Greven, Maureen P. Neary, Raluca Ionescu‐Ittu, Bruno Emond, Mei Sheng Duh, Floor Jansen, Bernard A. Zonnenberg
Publikováno v:
Epilepsia Open, Vol 4, Iss 4, Pp 581-592 (2019)
Abstract Objective To estimate health‐related quality of life (HRQoL) in patients with tuberous sclerosis complex (TSC) and associated manifestations and to identify potential factors associated with HRQoL in this population of patients. Methods We
Externí odkaz:
https://doaj.org/article/14fdadbaa9134783972133ae0b26ebf0
Autor:
Peter Mohr, Felix Kiecker, Virtudes Soriano, Olivier Dereure, Karmele Mujika, Philippe Saiag, Jochen Utikal, Rama Koneru, Caroline Robert, Florencia Cuadros, Matias Chacón, Rodrigo U Villarroel, Yana G Najjar, Lisa Kottschade, Eva M Couselo, Roy Koruth, Annie Guérin, Rebecca Burne, Raluca Ionescu-Ittu, Maurice Perrinjaquet, Jonathan S Zager
Publikováno v:
Melanoma Management, Vol 6, Iss 4 (2019)
Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011–2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Ch
Externí odkaz:
https://doaj.org/article/3793d2a3b1484aed83d8938e4ccc0f12
Autor:
Francis Vekeman, Lisa Weiss, Jalal Aram, Raluca Ionescu-Ittu, Shahrzad Moosavi, Yongling Xiao, Wendy Y. Cheng, Rachel H. Bhak, Margaret Tawadrous, M. Rita Capparella, Philippe Montravers, Mei Sheng Duh
Publikováno v:
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-15 (2018)
Abstract Background To compare the risk of severe hepatotoxicity with anidulafungin versus caspofungin and micafungin in hospitalized adults. Methods This retrospective cohort study combined data from two large US- based hospital electronic medical r
Externí odkaz:
https://doaj.org/article/2bc70e7a6b23451a84cceef3af32f125
Autor:
Bernard A Zonnenberg, Maureen P Neary, Mei Sheng Duh, Raluca Ionescu-Ittu, Jonathan Fortier, Francis Vekeman
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0204646 (2018)
OBJECTIVE:To compare kidney size (used as proxy for total renal angiomyolipoma [rAML] size) and kidney function outcomes between patients with tuberous sclerosis complex (TSC) and rAML treated and not treated with everolimus. METHODS:Medical charts o
Externí odkaz:
https://doaj.org/article/a62ba8eb21714c2bb0d6c46519af0781
Autor:
John A. Eisman, Bernard Cortet, Mitra Boolell, Raluca Ionescu-Ittu, Francis Vekeman, Julie Heroux, Friederike Thomasius
Publikováno v:
Osteoporosis International. 34:977-991
Autor:
Neal D. Shore, Louise Yu, Dominique Lejeune, S. Ghate, François Laliberté, Jeri Kim, Lingfeng Yang, Mei Sheng Duh, Malena Mahendran, Raluca Ionescu-Ittu
Publikováno v:
Clinical Genitourinary Cancer. 19:480-490
Background Real-world evidence suggest that next generation hormonal agents (NHAs) abiraterone and enzalutamide were preferred as first-line (1L) therapies for metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) pre-2020